These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 15761672)

  • 1. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
    Dressler D; Bigalke H
    J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-induced failure of botulinum toxin type B therapy in de novo patients.
    Dressler D; Bigalke H
    Eur Neurol; 2004; 52(3):132-5. PubMed ID: 15479980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B.
    Dressler D; Lange M; Bigalke H
    Mov Disord; 2005 Dec; 20(12):1617-9. PubMed ID: 16078216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin type B for cervical dystonia.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?
    Dressler D; Münchau A; Bhatia KP; Quinn NP; Bigalke H
    Eur Neurol; 2002; 47(2):118-21. PubMed ID: 11844901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.
    Dressler D; Hallett M
    Eur J Neurol; 2006 Feb; 13 Suppl 1():11-5. PubMed ID: 16417592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type B for cervical dystonia.
    Marques RE; Duarte GS; Rodrigues FB; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD004315. PubMed ID: 27176573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Initial experiences with clinical use of botulinum toxin type B].
    Dressler D; Benecke R
    Nervenarzt; 2002 Feb; 73(2):194-8. PubMed ID: 11975099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
    Dressler D
    Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of non-A botulinum toxins: botulinum toxin type B.
    Dressler D; Eleopra R
    Neurotox Res; 2006 Apr; 9(2-3):121-5. PubMed ID: 16785108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
    Duarte GS; Castelão M; Rodrigues FB; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004314. PubMed ID: 27782297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
    Dressler D; Kupsch A; Seitzinger A; Paus S
    Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.
    Jankovic J; Hunter C; Dolimbek BZ; Dolimbek GS; Adler CH; Brashear A; Comella CL; Gordon M; Riley DE; Sethi K; Singer C; Stacy M; Tarsy D; Atassi MZ
    Neurology; 2006 Dec; 67(12):2233-5. PubMed ID: 17190952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences.
    Barnes MP; Best D; Kidd L; Roberts B; Stark S; Weeks P; Whitaker J
    Eur J Neurol; 2005 Dec; 12(12):947-55. PubMed ID: 16324088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
    Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.
    Dressler D; Benecke R
    Eur Neurol; 2003; 49(1):34-8. PubMed ID: 12464716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin therapy for cervical dystonia.
    Jankovic J
    Neurotox Res; 2006 Apr; 9(2-3):145-8. PubMed ID: 16785112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy.
    Dressler D; Bigalke H
    Mov Disord; 2002 Jan; 17(1):170-3. PubMed ID: 11835457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.